Hereditary Motor And Sensory Neuropathy With Agenesis Of The Corpus Callosum
Summary
Clinical characteristics.
Hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC), a neurodevelopmental and neurodegenerative disorder, is characterized by severe progressive sensorimotor neuropathy with resulting hypotonia, areflexia, and amyotrophy, and by variable degrees of dysgenesis of the corpus callosum. Mild-to-severe intellectual disability and "psychotic episodes" during adolescence are observed. Sensory modalities are moderately to severely affected beginning in infancy. The average age of onset of walking is 3.8 years; the average age of loss of walking is 13.8 years; the average age of death is 33 years.
Diagnosis/testing.
The diagnosis of HMSN/ACC is established in a proband with suggestive findings and biallelic pathogenic variants in SLC12A6 identified by molecular genetic testing.
Management.
Treatment of manifestations: Walking aids such as canes or walkers are required. As the disease progresses, orthoses for upper and lower limbs and physiotherapy are needed to prevent contractures. Early developmental/educational intervention addresses cognitive delays. Depending on severity, individuals with HMSN/ACC usually require corrective surgery for scoliosis. Neuroleptics may be used to treat psychiatric manifestations, usually during adolescence.
Surveillance: Monitor in the early teens for scoliosis and in the late teens for psychiatric manifestations.
Genetic counseling.
HMSN/ACC is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Heterozygotes (carriers) are asymptomatic. Once the SLC12A6 pathogenic variants have been identified in an affected family member, carrier testing for at-risk family members and prenatal and preimplantation genetic testing are possible.
Diagnosis
Consensus diagnostic criteria for hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC) have not been established.
Suggestive Findings
Hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC) should be suspected in individuals with the following clinical, electrophysiologic, and neuroimaging findings, and family history [Dupré et al 2003].
Clinical findings
- Severe progressive sensorimotor neuropathy with areflexia
- Developmental delay / intellectual disability ranging from mild to severe
Electrophysiology
- Sensory nerve action potentials cannot be recorded at the median, ulnar, or sural nerves even in children in their first year of life.
- Compound motor action potentials usually show diminished amplitudes.
- Nerve conduction velocities for the median, ulnar, and tibial nerves are variable.
- Needle electromyography may show mild signs of active denervation (e.g., fibrillation potentials).
Neuroimaging
- Brain MRI showing complete agenesis of the corpus callosum in 60% of individuals (Figure 1A, 2A), partial agenesis in 10%, and normal corpus callosum in 30% (Figure 1B, 2B)
- Mild cortical or cerebellar atrophy at a later age
Figure 1.
Figure 2.
Family history consistent with autosomal recessive inheritance (e.g., affected sibs and/or parental consanguinity). Absence of a known family history does not preclude the diagnosis.
Establishing the Diagnosis
The diagnosis of hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC) is established in a proband with suggestive findings and biallelic pathogenic variants in SLC12A6 identified by molecular genetic testing (see Table 1).
Note: Identification of biallelic SLC12A6 variants of uncertain significance (or identification of one known SLC12A6 pathogenic variant and one SLC12A6 variant of uncertain significance) does not establish or rule out a diagnosis of this disorder.
Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing or multigene panel) and comprehensive genomic testing (exome sequencing, exome array, genome sequencing) depending on the phenotype.
Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Individuals with the distinctive findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those in whom the diagnosis of HMSN/ACC has not been considered are more likely to be diagnosed using genomic testing (see Option 2).
Option 1
Single-gene testing. Sequence analysis of SLC12A6 is performed first to detect small intragenic deletions/insertions and missense, nonsense, and splice site variants. Note: Depending on the sequencing method used, single-exon, multiexon, or whole-gene deletions/duplications may not be detected. If only one or no variant is detected by the sequencing method used, the next step is to perform gene-targeted deletion/duplication analysis to detect exon and whole-gene deletions or duplications.
Note: In individuals of French Canadian origin who have the typical phenotype, targeted analysis for the c.2436+1delG pathogenic variant can be performed first, followed by sequence analysis if only one or no variant is identified.
An agenesis of the corpus callosum panel, an intellectual disability panel, or a comprehensive neuropathy panel (multigene panels that include SLC12A6 and other genes of interest; see Differential Diagnosis) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
Option 2
Comprehensive genomic testing does not require the clinician to determine which gene is likely involved. Exome sequencing is most commonly used; genome sequencing is also possible.
If exome sequencing is not diagnostic, exome array (when clinically available) may be considered to detect (multi)exon deletions or duplications that cannot be detected by sequence analysis.
For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.
Table 1.
Gene 1 | Method | Proportion of Pathogenic Variants 2 Detectable by Method |
---|---|---|
SLC12A6 | Sequence analysis 3 | >90% 4, 5 |
Gene-targeted deletion/duplication analysis 6 | 1 reported 7 |
- 1.
See Table A. Genes and Databases for chromosome locus and protein.
- 2.
See Molecular Genetics for information on variants detected in this gene.
- 3.
Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
- 4.
Howard et al [2002], Uyanik et al [2006], and data derived from the subscription-based professional view of Human Gene Mutation Database [Stenson et al 2017]
- 5.
Nearly all (>99%) individuals of French Canadian descent, who make up most of the affected population, have the c.2436+1delG variant, which is detectable by sequence analysis.
- 6.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
- 7.
Antoniadi et al [2015]
Clinical Characteristics
Clinical Description
Hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC) is both a neurodevelopmental disorder (with variable degrees of dysgenesis of the corpus callosum and mild-to-severe intellectual disability) and a neurodegenerative disorder (severe progressive sensorimotor neuropathy).
The neurologic findings of HMSN/ACC in 64 individuals (ages 2 to 34 years) in the French Canadian population reported by Mathieu et al [1990] are summarized in Table 2, with additional information from Larbrisseau et al [1984], Salin-Cantegrel et al [2007], and Auer et al [2016].
Table 2.
Feature | % of Persons w/Feature | Comment | |
---|---|---|---|
Motor & sensory neuropathy | 100% | ||
Cranial nerve involvement | Ptosis | 33%-59% | Symmetric or asymmetric |
Gaze palsy | 13%-30% | ||
Horizontal nystagmus | 20% | ||
Facial weakness | 34%-100% | Symmetric or asymmetric; may be assoc w/hemifacial atrophy | |
Cognitive function | Normal | 8% | Based on Taft clinical classification to stratify cognitive function in 53 persons 1 |
Mild ID | 49% | ||
Moderate ID | 40% | ||
Severe ID | 4% | ||
Psychotic episodes | 39% (25/64) | After age 15 yrs 1 | |
Scoliosis | 86% | Average onset age 10.4 yrs | |
Pulmonary restrictive syndrome | Unknown | Related to scoliosis & axonal loss affecting respiratory muscles 2 | |
Contractures | 59% | MCP joint (flexion) contracture | |
50% | Valgus foot deviation | ||
47% | Early Achilles tendon retraction | ||
31% | Varus foot deviation | ||
Seizures | 17% | Generalized, absence, or focal seizures 3 | |
Tremor | 25% |
ID = intellectual disability; MCP = metacarpophalangeal
Based on Larbrisseau et al [1984] and Mathieu et al [1990]
- 1.
Mathieu et al [1990]
- 2.
Auer et al [2016]
- 3.
Salin-Cantegrel et al [2007]
Progressive motor and sensory neuropathy
- Reflexes invariably absent from infancy
- Hypotonia invariably present in the first year of life
- Progressive distal and proximal symmetric limb weakness
- Muscle atrophy
- Diffuse limb tremor (probably secondary to polyneuropathy)
- Contractures
- Loss of sensation to touch and pinprick in a glove and stocking distribution; easier to evaluate in older children
The average age of onset for sitting alone is 2.1 years, for standing is more than two years, for walking is 3.8 years, and average age of loss of ability to walk is 13.8 years.
Cognitive function. The Taft clinical classification uses an IQ test to rank individuals in four categories: normal intelligence (IQ >75), mild intellectual disability (IQ = 50-75), moderate intellectual disability (IQ = 25-50), and severe intellectual disability (IQ <25). Individuals with mild intellectual disability can achieve five to six years of elementary school and live independently. Individuals with moderate intellectual disability can help with activities of daily living but require supervision on a daily basis. Individuals with severe intellectual disability require assistance for daily living and supervision but may be able to take care of some routine daily needs. The range of intelligence of individuals with HSMN/ACC is normal IQ to severe intellectual disability.
Psychotic episodes. Mathieu et al [1990] reported that after age 15 years, 39% (25/64) developed "psychotic episodes" characterized by paranoid delusions, depressive states, visual hallucinations, auditory hallucinations, or "autistic-like" features.
Life expectancy. Average age of death is 33 years and is usually related to respiratory insufficiency [Larbrisseau & Sarnat 2017].
Other
- Lumbar puncture usually reveals mild elevation of CSF proteins [Dupré et al 2003].
- Sural nerve biopsy shows an almost total lack of large myelinated fibers, signs of axonal loss (ovoids of Wallerian degeneration), and some enlarged axons that on electron microscopy show decreased density of neurofilaments. Isolated fibers may have disproportionately thin myelin sheaths, suggesting that the axoplasm is swollen. Electron microscopy may show decreased packing density of neurofilaments, without signs of their degradation [Dupré et al 2003, Auer et al 2016].Note: Sural nerve biopsy is unnecessary to confirm the diagnosis, now that molecular genetic testing is possible.
- EEG may be normal or with epileptiform abnormalities [Dupré et al 2003, Salin-Cantegrel et al 2007].
- Muscle biopsy shows nonspecific signs of chronic denervation atrophy [Dupré et al 2003, Auer et al 2016].
Autopsy examination. The hallmark is swollen axons in cranial nerve samples (especially cranial nerves 3 and 7), as well as in the dorsal and ventral nerve roots. Swollen axons can also be scattered in the white matter. The brain shows either no agenesis of the corpus callosum (ACC), partial ACC, or complete ACC with preservation of Probst bundle [Dupré et al 2003, Auer et al 2016].
Genotype-Phenotype Correlations
The data from affected individuals are insufficient to establish genotype-phenotype correlations.
Nomenclature
HMSN/ACC may also be referred to as Charlevoix disease.
Prevalence
In the French Canadian population of the Saguenay and Lac-St-Jean regions of Quebec, Canada, the overall incidence of HMSN/ACC is 1:2,117 live births; the carrier rate is 1:23 inhabitants due to the c.2436+1delG (also known as c.2436delG) founder variant. Otherwise, HMSN/ACC is extremely rare worldwide. Three pairs of sibs (of Italian, Mexican, and Turkish origin) have been reported to have molecularly confirmed HMSN/ACC.
Differential Diagnosis
Table 3.
Gene(s) | Disorder | Clinical Characteristics | Features of Differential Disorder Distinguishing It from HMSN/ACC |
---|---|---|---|
EGR2 FGD4 FIG4 GDAP1 MTMR2 NDRG1 PRX SBF1 SBF2 SH3TC2 | Autosomal recessive HMSN (previously CMT4; see CMT Overview) | Severe early-onset neuropathy | Absence of ID & dysgenesis of CC |
PLA2G6 | Classic infantile neuroaxonal dystrophy (INAD; see PLA2G6 Neurodegeneration) |
|
|
ARSA | Arylsulfatase A deficiency (metachromatic leukodystrophy [MLD]) |
|
|
GAN | Giant axonal neuropathy (GAN) |
|
|
SPG11 | Spastic paraplegia 11 (SPG11) |
|
|
GALC | Krabbe disease (GALC deficiency, globoid cell leukodystrophy) |
|
|
ACC = agenesis of corpus callosum; CC = corpus callosum; CNS = central nervous system; DD = developmental delay; HMSN = hereditary motor and sensory neuropathy; ID = intellectual disability
- 1.
Atypical neuroaxonal dystrophy is more varied than the classic form. In general, onset is in early childhood, but can be as late as the late teens. The presenting signs may be similar to the classic form with gait instability or ataxia, but may be speech delay and autistic features, which may remain as the only evidence of disease for a year or more. The course is fairly stable during early childhood and resembles static encephalopathy, but is followed by neurologic deterioration between ages seven and 12 years.
Management
Consensus clinical management recommendations for hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC) have not been published.
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC), the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
System/Concern | Evaluation | Comment |
---|---|---|
Motor & sensory neuropathy | Neurologic exam |
|
Seizures | ||
Musculoskeletal | Orthopedics / physical medicine & rehab / PT/OT eval | To incl assessment of:
|
Scoliosis | Orthopedics & pulmonary medicine |
|
Extraocular muscle involvement | Ophthalmologic exam | Assess for ptosis, esotropia or exotropia, gaze palsy, & nystagmus. |
Developmental delay / Intellectual disability | Developmental assessment |
|
Psychotic episodes | Obtain history of possible events. | When concerns, refer for psychiatric eval. |
Genetic counseling | By genetics professionals 1 | To inform affected persons & their families re nature, MOI, & implications of HMSN/ACC to facilitate medical & personal decision making |
Family support/ resources | Assess:
|
ADL = activities of daily living; MOI = mode of inheritance; OT = occupational therapy; PT = physical therapy
- 1.
Medical geneticist, certified genetic counselor, or certified advanced genetic nurse
Treatment of Manifestations
Care is best provided by a multidisciplinary team that comprises a pediatrician or pediatric neurologist, developmental pediatrician, psychiatrist, orthopedist, physiotherapist, and occupational therapist.
Table 5.
Manifestation/Concern | Treatment | Considerations/Other |
---|---|---|
Seizures | Standardized treatment w/AEDs by experienced neurologist |
|
Extraocular muscle involvement | Standard treatment(s) per ophthalmologist | |
Musculoskeletal | Orthopedics / physical medicine & rehab / PT/OT |
|
Scoliosis | Orthopedics | Depending on degree of severity, scoliosis usually requires surgical correction. |
Pulmonary medicine | Intervention per standard care | |
Developmental delay / Intellectual disability | See Developmental Delay / Intellectual Disability Management Issues. | |
Psychotic episodes |